# OnCo record nct03888105 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03888105/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03888105", "NCT03888105" ;
  schema:name "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat"@en ;
  schema:alternateName "ELM-2"@en, "Odronextamab in relapsed or refractory B-cell non-Hodgkin lymphoma"@en ;
  schema:description "A phase 2 trial of Odronextamab in hodgkin lymphoma and non-hodgkin lymphoma, run by Regeneron Pharmaceuticals, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03888105/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03888105> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2019-11-13" ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/> ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd3/> ;
  onco:drugs <https://onco.cc/drugs/odronextamab/> ;
  onco:companies <https://onco.cc/companies/regeneron/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/> .